Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
May 17 2021 - 04:05PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced
that it is postponing its previously announced investor conference
call scheduled to be held on Monday, May 17, 2021, at 2 p.m.
Pacific Time. The company filed a Form 12b-25 with the Securities
and Exchange Commission today in order to extend the due date of
its Quarterly Report on Form 10-Q for the three months ended March
31, 2021, by five calendar days as permitted by Rule 12b-25 under
the Securities Exchange Act of 1934, and is postponing the investor
call in light of that filing delay. The company will announce a new
date and time for a rescheduled investor call.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
company’s SYMJEPI® (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. In addition to its naloxone
injection product candidate, ZIMHI™, Adamis is developing
additional products, including treatments for acute respiratory
diseases, such as COVID-19, influenza, asthma and COPD. The
company’s subsidiary, US Compounding Inc., compounds sterile
prescription drugs, and certain nonsterile drugs for human and
veterinary use by hospitals, clinics, surgery centers, and vet
clinics throughout most of the United States. For additional
information about Adamis Pharmaceuticals, please visit
www.adamispharmaceuticals.com.
Contact:
Adamis Investor Relations Robert UhlManaging DirectorWestwicke
ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2023 to Mar 2024